help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-0614
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/9/3404    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow patientINFORMation
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonds, D. E.
Right arrow Articles by Margolis, K. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonds, D. E.
Right arrow Articles by Margolis, K. L.
Related Collections
Right arrow Calcium and Bone Metabolism
Right arrow Diabetes and Insulin
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 9 3404-3410
Copyright © 2006 by The Endocrine Society

Risk of Fracture in Women with Type 2 Diabetes: the Women’s Health Initiative Observational Study

Denise E. Bonds, Joseph C. Larson, Ann V. Schwartz, Elsa S. Strotmeyer, John Robbins, Beatriz L. Rodriguez, Karen C. Johnson and Karen L. Margolis

Departments of Epidemiology and Prevention and Internal Medicine (D.E.B.), Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157; Fred Hutchinson Cancer Research Center (J.C.L.), Seattle, Washington 98109; Department of Epidemiology and Biostatistics (A.V.S.), University of California San Francisco, San Francisco, California 94105; Department of Epidemiology (E.S.S.), University of Pittsburgh, Pittsburgh, Pennsylvania 15213; Department of Internal Medicine (J.R.), University of California, Davis, Davis, California 95817; Department of Geriatric Medicine (B.L.R.), University of Hawaii at Manoa, Honolulu, Hawaii 96817; Department of Preventive Medicine (K.C.J.), University of Tennessee Health Science Center, Memphis Tennessee 38105; and HealthPartners Research Foundation (K.L.M.), Minneapolis, Minnesota 55440-1524

Address all correspondence and requests for reprints to: Denise E. Bonds, M.D., M.P.H., Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157. E-mail: dbonds{at}wfubmc.edu.

Context: Some but not all studies have shown higher rates of fracture in individuals with type 2 diabetes.

Objective: The objective of the study was to determine the risk of fracture in postmenopausal women with type 2 diabetes and determine whether risk varies by fracture site, ethnicity, and baseline bone density.

Design, Setting, and Participants: Women with clinically diagnosed type 2 diabetes at baseline in the Women’s Health Initiative Observational Cohort, a prospective study of postmenopausal women (n = 93,676), were compared with women without diagnosed diabetes and risk of fracture overall and at specific sites determined.

Main Outcome Measures: All fractures and specific sites separately (hip/pelvis/upper leg; lower leg/ankle/knee; foot; upper arm/shoulder/elbow; lower arm/wrist/hand; spine/tailbone) were measured. Bone mineral density (BMD) in a subset also was measured.

Results: The overall risk of fracture after 7 yr of follow-up was higher in women with diabetes at baseline after controlling for multiple risk factors including frequency of falls [adjusted relative risk (RR) 1.20, 95% confidence interval (CI) 1.11–1.30]. In a subsample of women with baseline BMD scores, women with diabetes had greater hip and spine BMD. The elevated fracture risk was found at multiple sites (hip/pelvis/upper leg; foot; spine/tailbone) among black women (RR 1.33, 95% CI 1.00–1.75) and women with increased baseline bone density (RR 1.26, 95% CI 0.96–1.66).

Conclusion: Women with type 2 diabetes are at increased risk for fractures. This risk is also seen among black and non-Hispanic white women after adjustment for multiple risk factors including frequent falls and increased BMD (in a subset).


Find additional patient-related information at:

Diabetes and the Chance of Bone Fractures


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
B. Tao, J.-M. Liu, H.-Y. Zhao, L.-H. Sun, W.-Q. Wang, X.-Y. Li, and G. Ning
Differences between Measurements of Bone Mineral Densities by Quantitative Ultrasound and Dual-Energy X-Ray Absorptiometry in Type 2 Diabetic Postmenopausal Women
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1670 - 1675.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
S. E. Kahn, B. Zinman, J. M. Lachin, S. M. Haffner, W. H. Herman, R. R. Holman, B. G. Kravitz, D. Yu, M. A. Heise, R. P. Aftring, et al.
Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)
Diabetes Care, May 1, 2008; 31(5): 845 - 851.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
C. Meier, M. E. Kraenzlin, M. Bodmer, S. S. Jick, H. Jick, and C. R. Meier
Use of Thiazolidinediones and Fracture Risk
Arch Intern Med, April 28, 2008; 168(8): 820 - 825.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. Monami, B. Cresci, A. Colombini, L. Pala, D. Balzi, F. Gori, V. Chiasserini, N. Marchionni, C. M. Rotella, and E. Mannucci
Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients: A case-control study
Diabetes Care, February 1, 2008; 31(2): 199 - 203.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Grey, M. Bolland, G. Gamble, D. Wattie, A. Horne, J. Davidson, and I. R. Reid
The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1305 - 1310.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society